Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entecavir vs Lamivudine in HBeAg-Negative Chronic Hepatitis B
NCT00393484Phase 4Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2007
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of entecavir in Chronic Hepatitis B (CHB) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Percentage of Participants Who Achieved a Virologic Response at Week 24. Started Feb 2007; status: completed.
02
Drugs
entecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00393484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00393484.